ResMed Stock Forecast, Price & News

$285.95
-0.23 (-0.08 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$284.00
$287.86
50-Day Range
$248.76
$297.36
52-Week Range
$165.72
$301.34
Volume917,484 shs
Average Volume594,373 shs
Market Capitalization$41.66 billion
P/E Ratio88.26
Dividend Yield0.59%
Beta0.3
30 days | 90 days | 365 days | Advanced Chart
Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.


ResMed logo

About ResMed

ResMed, Inc. engages in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. It operates through the Sleep and Respiratory Care, and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment engages in the supply of business management software as a service to out-of-hospital health providers. Its product portfolio includes devices, diagnostic products, mask systems, headgear and other accessories, and dental devices. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.06 out of 5 stars

Medical Sector

488th out of 1,350 stocks

Surgical & Medical Instruments Industry

48th out of 123 stocks

Analyst Opinion: 2.0Community Rank: 3.5Dividend Strength: 1.7Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











ResMed (NYSE:RMD) Frequently Asked Questions

Is ResMed a buy right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 3 sell ratings, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ResMed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RMD, but not buy additional shares or sell existing shares.
View analyst ratings for ResMed
or view top-rated stocks.

What stocks does MarketBeat like better than ResMed?

Wall Street analysts have given ResMed a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ResMed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ResMed?

ResMed saw a increase in short interest during the month of August. As of August 13th, there was short interest totaling 1,230,000 shares, an increase of 16.0% from the July 29th total of 1,060,000 shares. Based on an average daily trading volume, of 560,300 shares, the days-to-cover ratio is currently 2.2 days. Approximately 0.9% of the company's shares are short sold.
View ResMed's Short Interest
.

When is ResMed's next earnings date?

ResMed is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for ResMed
.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) announced its earnings results on Thursday, August, 5th. The medical equipment provider reported $1.35 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.25 by $0.10. The medical equipment provider earned $876.10 million during the quarter, compared to analysts' expectations of $781.10 million. ResMed had a net margin of 14.84% and a trailing twelve-month return on equity of 28.03%. During the same period last year, the company earned $1.33 earnings per share.
View ResMed's earnings history
.

How has ResMed's stock price been impacted by COVID-19 (Coronavirus)?

ResMed's stock was trading at $153.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RMD shares have increased by 86.2% and is now trading at $285.95.
View which stocks have been most impacted by COVID-19
.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a quarterly dividend on Thursday, August 5th. Stockholders of record on Thursday, August 19th will be paid a dividend of $0.42 per share on Thursday, September 23rd. This represents a $1.68 annualized dividend and a yield of 0.59%. The ex-dividend date is Wednesday, August 18th. This is a boost from ResMed's previous quarterly dividend of $0.39.
View ResMed's dividend history
.

Is ResMed a good dividend stock?

ResMed pays an annual dividend of $1.68 per share and currently has a dividend yield of 0.59%. The dividend payout ratio of ResMed is 31.52%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ResMed will have a dividend payout ratio of 25.19% next year. This indicates that ResMed will be able to sustain or increase its dividend.
View ResMed's dividend history.

What price target have analysts set for RMD?

12 equities research analysts have issued twelve-month target prices for ResMed's shares. Their forecasts range from $210.00 to $270.00. On average, they anticipate ResMed's share price to reach $241.50 in the next year. This suggests that the stock has a possible downside of 15.5%.
View analysts' price targets for ResMed
or view top-rated stocks among Wall Street analysts.

Who are ResMed's key executives?

ResMed's management team includes the following people:
  • Mick Farrell, Chief Executive Officer & Director
  • Rob Douglas, President & Chief Operating Officer
  • Brett A. Sandercock, Chief Financial Officer
  • Carlos M. Nunez, Chief Medical Officer
  • Bobby Ghoshal, Chief Technology Officer

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed CEO Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among ResMed's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ResMed's key competitors?

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), The Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

Who are ResMed's major shareholders?

ResMed's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.59%), BlackRock Inc. (8.70%), WCM Investment Management LLC (6.26%), State Street Corp (4.26%), FMR LLC (2.89%) and Baillie Gifford & Co. (2.23%). Company insiders that own ResMed stock include Brett Sandercock, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends for ResMed
.

Which institutional investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Franklin Resources Inc., Los Angeles Capital Management LLC, JPMorgan Chase & Co., CIBC Asset Management Inc, Prudential Financial Inc., Nuveen Asset Management LLC, and Bank of America Corp DE. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Rajwant Sodhi, Robert Andrew Douglas, and Ronald R Taylor.
View insider buying and selling activity for ResMed
or view top insider-selling stocks.

Which institutional investors are buying ResMed stock?

RMD stock was purchased by a variety of institutional investors in the last quarter, including Amundi, Ownership Capital B.V., Geode Capital Management LLC, Alyeska Investment Group L.P., Morgan Stanley, Morgan Stanley, Baillie Gifford & Co., and Price T Rowe Associates Inc. MD.
View insider buying and selling activity for ResMed
or or view top insider-buying stocks.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $285.95.

How much money does ResMed make?

ResMed has a market capitalization of $41.66 billion and generates $3.20 billion in revenue each year. The medical equipment provider earns $474.51 million in net income (profit) each year or $5.33 on an earnings per share basis.

How many employees does ResMed have?

ResMed employs 7,970 workers across the globe.

When was ResMed founded?

ResMed was founded in 1989.

What is ResMed's official website?

The official website for ResMed is www.resmed.com.

Where are ResMed's headquarters?

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at (858) 836-5000 or via email at [email protected].


This page was last updated on 9/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.